Harsha Rajasimha, MS, PhD, Founder, Jeeva Informatics Solutions, Inc.; Founder and Chairman, IndoUSrare; Co-Director, Rare Diseases Systems Biology Initiative, George Mason University After losing a child to a rare congenital disease, Dr. Rajasimha became determined to apply his clinical genomics data research experience to develop solutions to help accelerate clinical research leading to faster cures for rare disease.
Over the past twenty years, the world has faced several infectious disease outbreaks including; Ebola, Influenza A (H1N1), SARS, MERS, Zika virus and now COVID-19. With over 200k deaths worldwide, COVID-19 has brought an enormous strain on our health resources, but also has had a massive impact on human health and the economy.
Transcript John: We would like to welcome you to the Sanguine Speaker Series webinar, The Journey From Patient to Advocate to Leader: Changing the Clinical Research Game, presented by Rob Long. Rob is the executive director of Uplifting Athletes. I will now hand it over to Rob.
COVID-19 has put the biopharma industry into a tailspin – big pharma, biotech and small startups are all emerging in the development of a treatment and vaccine for this pandemic. Will COVID-19 change the current R&D landscape and create a new norm for the biopharma industry? Moderator: Joan Koerber-Walker President and CEO, Arizona BioIndustry Association (AZBio) Panelists: Brian Neman Co-Founder and CEO, Sanguine Todd Parsley Director of Preclinical Research, Infectious Diseases at Noble Life Sciences Inc Chris Moore, PhD Senior Director, Immunology, Arbutus Biopharma, Inc.
COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. In this Sanguine Speaker Series (3) virtual fireside chat, we will discuss: Response efforts to the current COVID-19 pandemic How does the race for the cure affect the hundreds of other drugs in development COVID-19’s potential impact on the global pharmaceutical market?
Speaker: Kelly M. Knee, PhD, Senior Principal Scientist, Rare Disease Researcher Unit, Pfizer Sickle cell disease is a severe genetic disorder caused by a single point mutation on the β-chain of adult hemoglobin (Hb A), β6 Glu→Val (Hb S). Numerous small molecules which covalently bind to Hb S have been evaluated clinically, however, the molecules that have demonstrated clinical efficacy all carry a reactive aldehyde group.
COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. Moderator: Craig Lipset Independent Advisor, Former Head of Clinical Innovation, Pfizer Panelists: Brian Neman CEO and Co-Founder, Sanguine Lisa Tindell Vice President, Clinical Research Operations at Minneapolis Heart Institute Foundation Sal Salamone Editor in Chief, RTInsights.com Transcript John: We would like to welcome you to the Sanguine Speaker Series Webinar on COVID-19; Navigating the Pandemic.
Author Sarah Gray shares her story of how she anonymously donated her infant son’s post-mortem tissue for biomedical research to some of the most prestigious scientific facilities in the country. Years later, after tracking down each donation, Sarah met with the research scientists that received the donations to learn how they are being studied in cutting-edge research for medical discoveries. One of these research scientists who received her son’s retinas is Dr.
Join our distinguished Novartis speaker, Shruthi Bharadwaj, PhD as she speaks about her experience in AI including: With the costs to commercialize a new drug is dramatically increasing to over $2 billion, AI brings the opportunity to assist pharma companies to bring new drugs and therapies to the market faster.
Research depends on samples from patients and healthy volunteers. However, obtaining biospecimens from human subjects can be a challenge for researchers and patients alike. Home-based specimen collection directly connects patients to researchers, while alleviating the burden of travel to secondary sites.